Skip to content


Bortezomib, Velcade (bortezomib) is a small molecule pharmaceutical. Bortezomib was first approved as Bortezomib on 2003-05-13. It is used to treat mantle-cell lymphoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. In addition, it is known to target proteasome subunit beta type-5 and proteasome subunit beta type-1. Velcade's patents are valid until 2032-11-03 (FDA).
Trade Name Velcade
Common Name Bortezomib
Indication mantle-cell lymphoma, multiple myeloma
Drug Class Proteozome inhibitors
Get full access now